What is the current stock price of BioPorto A/S (BIOPOR.CO)?

As of the latest market data, BioPorto A/S (BIOPOR.CO) is trading at $0.00. The stock has seen a loss of undefined% today.

Does BioPorto A/S (BIOPOR.CO) pay a dividend?

Based on current data, BioPorto A/S does not have a confirmed active dividend policy.

What is the market cap of BioPorto A/S?

The current market capitalization of BioPorto A/S (BIOPOR.CO) is approximately unavailable.

BIOPOR.CO

BioPorto A/S·Healthcare

0.00

0.000%(+0.00)

Market Closed

Last Updated: — ET

52W L: $0.0052W H: $0.00

BIOPOR.CO NEWS

globenewswire.com

Mar 31

KDIGO offentliggør udkast til klinisk praksis guideline 2026 for akut nyreskade og akut nyresygdom

31. marts 2026 Presse Meddelelse KDIGO offentliggør udkast til klinisk praksis guideline 2026 for akut nyreskade og akut nyresygdom KØBENHAVN, DANMARK, 31. marts 2026 - BioPorto A/S ("BioPorto" eller "Selskabet") (CPH: BIOPOR) meddelte i dag, at KDIGO har offentliggjort udkastet til Clinical Practice Guideline 2026 for Acute Kidney Injury (AKI) og Acute Kidney Disease (AKD), hvilket udgør den første væsentlige opdatering af de globale AKI‑retningslinjer siden 2012.

globenewswire.com

Mar 31

KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease

March 31, 2026News Release KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease COPENHAGEN, DENMARK, 31 March 2026 - BioPorto A/S ("BioPorto" or "Company") (CPH: BIOPOR) today announced that the KDIGO 2026 Clinical Practice Guideline Draft for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) has been published, which introduces the first major update to global AKI guidelines since 2012.

globenewswire.com

Feb 5

BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering

5. februar 2026Meddelelse nr. 1 BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering KØBENHAVN, DANMARK, 5. februar, 2026, (GLOBE NEWSWIRE) - BioPorto A/S CVR-nr. 17500317 (BioPorto eller Selskabet) (CPH: BIOPOR), annoncerede i dag foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering.

Company Profile

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

IPO Date

2000-01-13

Beta

1.12

Websitebioporto.com↗